Edition:
United States

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

8.20USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,901
52-wk High
$27.77
52-wk Low
$7.20

Chart for

About

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement... (more)

Overall

Beta: --
Market Cap(Mil.): $185.54
Shares Outstanding(Mil.): 22.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Dec 04 2017

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

Nov 09 2017

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2A6uuro) Further company coverage:

Nov 01 2017

BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56

* Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

* RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

Jul 31 2017

BRIEF-Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495

* Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh

Jun 27 2017

Earnings vs. Estimates